期刊文献+

吉非替尼联合紫杉醇对鼻咽癌HNE1细胞EGFR、STAT3蛋白磷酸化的影响及意义 被引量:2

下载PDF
导出
摘要 目的 探讨吉非替尼对紫杉醇诱导鼻咽癌细胞凋亡作用的影响及可能机制,为临床治疗提供依据.方法 取对数生长期鼻咽癌HNE1细胞接种于6孔板中并随机分为5组,对照组不行特殊处理,紫杉醇组及联合1、2、3组分别加入紫杉醇及紫杉醇+不同质量浓度吉非替尼,各组均培养48 h后以流式细胞术检测凋亡率;另取对数生长期HNE1细胞分别予紫杉醇(紫杉醇组)及紫杉醇+吉非替尼(联合组)处理,24 h后Western blot法检测表皮生长因子受体(EGFR)、信号转导和转录活化因子3(STAT3)及其磷酸化蛋白水平.结果 联合1~3组细胞凋亡率显著高于其他两组(F=13.107,P=0.001),且联合3组〉 2组〉 1组(P〈0.05);联合组p-EGFR、p-STAT3水平显著低于紫杉醇组.结论 吉非替尼对紫杉醇诱导的鼻咽癌细胞凋亡作用具有协同性,可能机制为影响EGFR下游分子及交联信号通路;本研究为吉非替尼联合紫杉醇在鼻咽癌靶向治疗中的应用提供了理论依据.
出处 《山东医药》 CAS 北大核心 2010年第23期46-47,共2页 Shandong Medical Journal
  • 相关文献

参考文献8

二级参考文献62

  • 1Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature, 2001, 411:355-65
  • 2胥宾.抗肿瘤药理学新论[M].北京:人民卫生出版社,2004.
  • 3Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res, 2006, 12:5268-72
  • 4Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer, 2005, 5: 341- 54
  • 5Grant S, Qiao L, Dent P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci, 2002, 7: 376-89
  • 6Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell, 2000, 103:211-25
  • 7Holbro T, Beerli RR, Maurer F, et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA, 2006, 100:8933-8
  • 8Lee-Hoeflich ST, Crocker L, Yao E, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res, 2008, 68:5878-87
  • 9Rocha-Lima CM, Soares HP, Raez IE, et al. EGFR targeting of solid tumors. Cancer Control, 2007, 14:295-304
  • 10Kim YT, Park SW, Kim JW. Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma. Gynecol Oncol, 2002, 87:84-9

共引文献23

同被引文献40

  • 1柴红,陈泽泉,余永利.甲状腺髓样癌靶向治疗新进展[J].上海交通大学学报(医学版),2011,31(10):1470-1474. 被引量:3
  • 2张冠中.培美曲塞与吉非替尼对人结肠癌细胞株作用的研究[D].中国人民解放军军医进修学院2011
  • 3Zhi Xiao,Nianhua Ding,Guiqing Xiao,Shouman Wang,Yuhui Wu,Lili Tang.Reversal of Multidrug Resistance by Gefitinib Via RAF1/ERK Pathway in Pancreatic Cancer Cell Line[J]. Anat Rec . 2012 (12)
  • 4David Adelstein,Cristina Rodriguez,Lisa Rybicki,Denise Ives,Thomas Rice.A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction[J]. Investigational New Drugs . 2012 (4)
  • 5Alessandro Antonelli,Poupak Fallahi,Silvia M. Ferrari,Ilaria Ruffilli,Francesca Santini,Michele Minuto,David Galleri,Paolo Miccoli.New Targeted Therapies for Thyroid Cancer[J]. Current Genomics . 2011 (8)
  • 6C. Gridelli,F. De Marinis,M. Di Maio,D. Cortinovis,F. Cappuzzo,T. Mok.Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence[J]. Lung Cancer . 2010 (3)
  • 7EleanorGutteridge,AmitAgrawal,RobertNicholson,KwokLeung Cheung,JohnRobertson,JuliaGee.The effects of gefitinib in tamoxifen‐resistant and hormone‐insensitive breast cancer: A phase II study[J]. Int. J. Cancer . 2010 (8)
  • 8Vuky Jacqueline,Porter Christopher,Isacson Christina,Vaughan Matthew,Kozlowski Paul,Picozzi Vincent,Corman John.Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. Cancer . 2009
  • 9Ohta Tsuyoshi,Ohmichi Masahide,Shibuya Tae,Takahashi Toshifumi,Tsutsumi Seiji,Takahashi Kazuhiro,Kurachi Hirohisa.Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells. Cancer biology & therapy . 2012
  • 10S. Carloni,F. Fabbri,G. Brigliadori,P. Ulivi,R. Silvestrini,D. Amadori,W. Zoli.Tyrosine Kinase Inhibitors Gefitinib, Lapatinib and Sorafenib Induce Rapid Functional Alterations in Breast Cancer Cells. Current Cancer Drug Targets . 2010

引证文献2

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部